References
- Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 53(1):109–38
- Allan L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322(7295): 1154–8
- Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life [The TTSFentanyl Comparative Trial Group]. J Pain Symptom Manage 1997;13(5):254–61
- Clark AJ, Ahmedzai SH, Allan LG, et al. Efficacy and safety of transdermal fentanyl and sustainedrelease oral morphine in patients with cancer and chronic noncancer pain. Curr Med Res Opin 2004;20(9):1419–28
- Gidwani S, Sathyan G, Sun T, Gupta SK. Pharmacokinetic investigation of dose proportionality across a new DTRANS® fentanyl matrix delivery system (DTRANS® fentanyl) dose range. Poster presentation. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M et al., editors. Pain practice. Blackwell Publishing; 2004. p. 288–9
- Mehdizadeh A, Toliate T, Rouini MR, Abashzadeh S, Dorkoosh F. Design and in vitro evaluation of new druginadhesive formulations of fentanyl transdermal patches. Acta Pharm 2004;54(4):301–17
- Andresen C, Cochien MS, Sun T, Gupta SK, Sathyan G. Evaluation of the skin sensitization potential of components of a new DTRANS® fentanyl matrix delivery system (DTRANS® fentanyl), exclusive of fentanyl (Placebo DTRANS®). Poster presentation, 24 September 2004. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, RuizLopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21–25, 2004, Barcelona, Spain. Pain practice. p. 288–9
- MLIC. Metropolitan height and weight tables. Stats Bull Met Life Insurance Company 1983;64:2–9
- Anderson LS, Grafelman DD, Carnes EJ, Sartwell CJ, Andaloro VJ, Lin PP. Development and validation of an exceptionally sensitive LC–MS/MS method to analyze fentanyl and naltrexone in human serum. AAPS PharmSci 2002;4(4):[abstract W5207]
- Portenoy RK, Southam MA, Gupta SK, et al. Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 1993;78(1):36–43
- Schuirmann DJ. A comparison of the two onesided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15(6):657–80
- Chow S, Liu J. Statistical methods for average bioavailability. In: Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker; 1992. p. 70–125
- FDA. Guidance for industry: statistical approaches to establishing bioequivalence. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001
- Gupta SK, Gidwani MS, Sun T, Sathyan G. Pharmacokinetic evaluation of a new DTRANS® fentanyl matrix delivery system (DTRANS® fentanyl) after single and repeated applications. Poster presentation, 24 September 2004. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, RuizLopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21–25, 2004, Barcelona, Spain. Pain practice. p. 288–9
- CPMP. Note for guidance on modified release oral and transdermal dosage forms: section II (pharmacokinetic and clinical evaluation). London: European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products; 1999
- Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000;38(1):59–89
- Sathyan G, Gidwani S, Sun T, Gupta SK. Evaluation of pharmacokinetic parameters in two skin types and age groups following a single application of a new DTRANS® fentanyl matrix delivery system (DTRANS® fentanyl). Poster presentation, 24 September 2004. 3rd World Congress of the World Institute of Pain, Barcelona, Spain, September, 2004. In: Devor M, Erdine S, RuizLopez R, editors. Book of abstracts 3rd World Congress World Institute of Pain, September 21–25, 2004, Barcelona, Spain. Pain practice. p. 2889
- Esteve M, Levron JC, Flaisler B, Schoefler P, Duvaldestin P, Chauvin M. Does aging modify pharmacokinetics of transdermal fentanyl? Anesthesiology 1991;75:A705